Renal and Cardiac Effects of DPP-4 Inhibitors – from Preclinical Development to Clinical Research

Renal impairment with sitagliptin: is there a need for active monitoring of potential renal toxicity?

(2014) JM Lestner et al.   BRITISH JOURNAL OF HOSPITAL MEDICINE

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

(2012) Odd Johansen et al.   Cardiovascular Diabetology

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

(2011) David W. Boulton et al.   CLINICAL PHARMACOKINETICS

Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects

(2011) C. G. Patel et al.   DIABETES OBESITY & METABOLISM

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

(2011) R. Kodera et al.   DIABETOLOGIA

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects

(2011) A. Karim et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product–receptor axis

(2011) Takanori Matsui et al.   PHARMACOLOGICAL RESEARCH

Effects of DPP-4 Inhibitors on the Heart in a Rat Model of Uremic Cardiomyopathy

(2011) Lyubov Chaykovska et al.   PLoS One

Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice

(2010) A. D. Dobrian et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Genetically manipulated progenitor cell sheet with diprotin A improves myocardial function and repair of infarcted hearts

(2010) Dongsheng Zhang et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats

(2010) SM Gardiner et al.   BRITISH JOURNAL OF PHARMACOLOGY

Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats

(2010) Barbara Huisamen et al.   CARDIOVASCULAR DRUGS AND THERAPY

Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome

(2010) David S Tofovic et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice

(2010) M. Sauve et al.   DIABETES

Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population

(2010) A. Schweizer et al.   DIABETES OBESITY & METABOLISM

The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

(2010) S. Blech et al.   DRUG METABOLISM AND DISPOSITION

Sitagliptin reduces albuminuria in patients with type 2 diabetes [Rapid Communication]

(2010) Sachiko Hattori   ENDOCRINE JOURNAL

Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans

(2010) Annis Marney et al.   HYPERTENSION

Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial) — Rationale, design and first interim analysis

(2010) Hans D. Theiss et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats

(2010) Bruna PM Pacheco et al.   JOURNAL OF HYPERTENSION

Effects of Sitagliptin Treatment on Dysmetabolism, Inflammation, and Oxidative Stress in an Animal Model of Type 2 Diabetes (ZDF Rat)

(2010) Liliana Ferreira et al.   MEDIATORS OF INFLAMMATION

GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats

(2010) Hui-Chun Ku et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

SDF-1 provides morphological and functional protection against renal ischaemia/reperfusion injury

(2010) G. Stokman et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes

(2010) Robert Frederich et al.   POSTGRADUATE MEDICINE

Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes

(2010) Jitendra Vaghasiya et al.   REGULATORY PEPTIDES

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

(2010) Debora Williams-Herman et al.   BMC Endocrine Disorders

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356) - investigations in DPP-4 deficient and wildtype rats

(2009) Silke Retlich et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Synergy between CD26/DPP-IV Inhibition and G-CSF Improves Cardiac Function after Acute Myocardial Infarction

(2009) Marc-Michael Zaruba et al.   Cell Stem Cell

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects

(2009) E. U. Graefe-Mody et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients

(2009) T. Heise et al.   DIABETES OBESITY & METABOLISM

Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

(2009) A. Fura et al.   DRUG METABOLISM AND DISPOSITION

Pathogenesis and Treatment of Microalbuminuria in Patients With Diabetes: The Road Ahead

(2009) Rigas Kalaitzidis et al.   Journal of Clinical Hypertension

Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants

(2009) Aziz Karim et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Concentration-dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans

(2009) Holger Fuchs et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

(2009) Cyrus DeSouza et al.   NATURE REVIEWS DRUG DISCOVERY

In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma

(2008) Marco M. Jost et al.   BIOCHEMICAL PHARMACOLOGY

Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

(2008) Kiwon Ban et al.   CIRCULATION

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

(2008) R CHRISTOPHER et al.   CLINICAL THERAPEUTICS

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

(2008) P COVINGTON et al.   CLINICAL THERAPEUTICS

Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use

(2008) D. P. Kao et al.   DIABETIC MEDICINE

Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans

(2008) H. He et al.   DRUG METABOLISM AND DISPOSITION

Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys

(2008) Bumsup Lee et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Sitagliptin Augments Sympathetic Enhancement of the Renovascular Effects of Angiotensin II in Genetic Hypertension

(2008) Edwin K. Jackson et al.   HYPERTENSION

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers

(2008) S. Hüttner et al.   JOURNAL OF CLINICAL PHARMACOLOGY

(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors

(2008) L. Thomas et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Intensive Glucose Lowering in Type 2 Diabetes

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE

EFFECTS OF DIPEPTIDYL PEPTIDASE IV INHIBITION ON ARTERIAL BLOOD PRESSURE

(2007) Edwin K Jackson et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY